Targeted radiation attack tested for Tough-to-Treat prostate cancer
Disease control
Terminated
This study tested whether adding a new targeted radiation drug to standard care could better control advanced prostate cancer that had spread and stopped responding to hormone therapy. The drug, 177Lu-DOTA-rosopatamab, is designed to seek out and deliver radiation directly to pro…
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC